Overview

Safety and Pharmacokinetic Study of Oral MK-8527 QM in Participants at Low-Risk for HIV-1 Infection (MK-8527-007)

Status:
Active, not recruiting
Trial end date:
2024-12-05
Target enrollment:
Participant gender:
Summary
This double-blind, placebo-controlled study is designed to assess the safety, tolerability, and pharmacokinetics of oral MK-8527 taken once monthly (QM) in participants at low risk for human immunodeficiency virus Type 1 (HIV-1) infection.
Phase:
Phase 2
Details
Lead Sponsor:
Merck Sharp & Dohme LLC